Table 1 Basline characteristics of included patients
From: Clinical characteristics and drug resistance of Nocardia in Henan, China, 2017–2023
Characteristics | N | (%) |
|---|---|---|
Mean age (range) (ys) | 56(18–85) | |
< 40 | 13/71 | 18.3 |
40–60 | 27/71 | 38 |
≥ 60 | 31/71 | 43.6 |
Male sex | 42/71 | 59.2 |
Occupational distribution | ||
Farmer | 48/71 | 67.6 |
Male sex | 29/48 | 60.4 |
Urban workers | 18/71 | 25.4 |
Others | 5/71 | 7 |
Departmental distribution of isolated strains | ||
Respiratory department | 43/71 | 60.6 |
Tuberculosis departmen | 17/71 | 23.9 |
Thoracic surgery | 6/71 | 8.5 |
Outpatient | 4/71 | 5.6 |
Cardiology department | 1/71 | 1.4 |
Infection types and sample sources | ||
Pulmonary nocardiosis | ||
Sputum | 37/71 | 52.1 |
Bronchoalveolar lavage fluid | 33/71 | 46.5 |
N. farcinica | 18/71 | 25.4 |
N. cyriacigeorgica | 13/71 | 18.3 |
N. abscessus | 8/71 | 11.3 |
N. amamiensis | 8/71 | 11.3 |
N. beijingensis | 5/71 | 7 |
N. otitidiscaviarum | 5/71 | 7 |
N. wallacei | 3/71 | 4.2 |
N. asiatica | 3/71 | 4.2 |
N. flavorosea | 2/71 | 2.8 |
N. africana | 2/71 | 2.8 |
N. rhamnosiphila | 1/71 | 1.4 |
N.pseudobrasiliensis | 1/71 | 1.4 |
N. puris | 1/71 | 1.4 |
Skin and subcutaneous nocardiosis | ||
Skin and soft tissue pus | 1/71 | 1.4 |
N. farcinica | 1/71 | 1.4 |
Smoking history | 17/71 | 23.9 |
History of drinking | 9/71 | 12.7 |
Diseases history | ||
Yes/No | 64/7 | 90.1/8.9 |
Underlying diseases | ||
Bronchiectasis | 39/71 | 54.9 |
Pulmonary tuberculosis | 16/71 | 22.5 |
Type 2 diabetes mellitus | 12/71 | 16.9 |
COPD | 8/71 | 11.3 |
Hypertension | 8/71 | 11.3 |
Anemia | 5/71 | 7 |
Coronary heart disease | 3/71 | 4.2 |
Sjogren's syndrome | 1/71 | 1.4 |
Chest radiograph | ||
Nodular or consolidative opacities | 66/66 | 100 |
Cavitary lesion | 16/66 | 24.2 |
Pleural effusion | 21/66 | 31.8 |
Laboratory data | ||
WBC increased | 22/65 | 33.8 |
Increased proportion of NEU(%) | 39/65 | 60 |
C-reactive protein elevation | 29/42 | 69 |
Increased ESR | 24/31 | 77.4 |
Co-infection | ||
Yes/No | 37/34 | 52.1/47.9 |
MTB | 16/37 | 43.2 |
Fungus (aspergillosis spp) | 5/37 | 13.5 |
NTM | 2/37 | .5.4 |
Other bacteria | 18/37 | 48.6 |
Treatment Plan | ||
TMP-SMX + One antibiotic | 10/61 | 16.4 |
TMP-SMX + Two or more antibiotics | 22/61 | 36.1 |
Amikacin + Other antibiotics | 20/61 | 32.8 |
Linezolid + Other antibiotics | 20/61 | 32.8 |
Quinolones + Other antibiotics | 24/61 | 39.3 |
Other antibiotic treatments | 17/61 | 27.9 |
Outcome | ||
Unknow | 3/71 | 4.2 |
Failer | 10/68 | 14.7 |
Recovered | 58/68 | 85.3 |